
Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
Melanocortin research peptide
PT-141
In stock
A cyclic melanocortin analogue used in controlled receptor-signalling and peptide-development research.
Order within — · ships today Cutoff 10:00 · local time
Arrives Sep 21 - Sep 23 to Europe
PT-141
38,50 €
Cyclic melanocortin analogue for MC3R, MC4R, and receptor-selectivity studies.
Scroll horizontally to reach every product-information tab.
Research overview
PT-141
PT-141 is the catalogue name for bremelanotide, a cyclic synthetic peptide associated with melanocortin-receptor research. Its constrained peptide design distinguishes it from linear melanocortin sequence references and supports controlled structure-and-signalling comparisons.
The authoritative database records establish compound identity, and the cited development report documents bremelanotide across a structured research programme. This literature supplies receptor-family and development context without defining a use or expected result for the product; the selected lot remains subject to its exact product record and signed analytical certificate.
Compound information
Specifications
Molecular profile
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Molecular mass
- 1025.2 g/mol
- CAS number
- 189691-06-3
- Molecular formula
- C50H68N14O10
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Synthetic cyclic melanocortin analogue; studied for central melanocortin receptor signalling and neuroendocrine pathway research; supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Latest test results
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

99.8%Purity by HPLC
Recorded QC panel
- AssayPeptide Screening 0.1% TFA
- 13.51 mg (± 0.07 mg)
- PurityPeptide Screening 0.1% TFA
- 99.8%
- Identity (FTIR)Peptide Screening 0.1% TFA
- 994 (± 5)
- Identity (RT)Retention time
- 0.997 (± 0.005)
- Bacterial endotoxinUSP 85 / Eur. Ph. 2.6.14
- 0.010 EU/mg
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
National Center for Biotechnology Information
PubChem Compound Summary: Bremelanotide
Authoritative identity record for the compound sold under the PT-141 catalogue name.
PubChem · View source ↗Chemical Abstracts Service
CAS Common Chemistry: 189691-06-3
Authoritative CAS Registry Number record for bremelanotide/PT-141.
CAS Common Chemistry · View source ↗Clayton AH, Kingsberg SA, Portman D, et al. · 2022
Safety Profile of Bremelanotide Across the Clinical Development Program
Primary clinical-development report for bremelanotide.
Journal of Women's Health · 10.1089/jwh.2021.0191 View source ↗National Center for Biotechnology Information
PubChem compound record
PubChem · View source ↗Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA · 2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Obstetrics and gynecology · View source ↗Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY · 2003
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Annals of the New York Academy of Sciences · View source ↗Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R · 2006
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
The journal of sexual medicine · View source ↗Edinoff AN, Sanders NM, Lewis KB, Apgar TL, Cornett EM, Kaye AM, Kaye AD · 2022



